The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway

Yuying Li,Wei Yan,Yu Qin,Liwei Zhang,Sheng Xiao

DOI: https://doi.org/10.3390/ijms25126468

IF: 5.6

2024-06-13

International Journal of Molecular Sciences

Abstract:Chemotherapy resistance in cancer is an essential factor leading to high mortality rates. Tumor multidrug resistance arises as a result of the autophagy process. Our previous study found that compound 1-nitro-2 acyl anthraquinone-leucine (C2) exhibited excellent anti-colorectal cancer (CRC) activity involving autophagy and apoptosis-related proteins, whereas its underlying mechanism remains unclear. A notable aspect of this study is how C2 overcomes the multidrug susceptibility of HCT116/L-OHP, a colon cancer cell line that is resistant to both in vitro and in vivo oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP). In a xenograft tumor mouse model, we discovered that the mixture of C2 and L-OHP reversed the resistance of HCT116/L-OHP cells to L-OHP and inhibited tumor growth; furthermore, C2 down-regulated the gene expression levels of P-gp and BCRP and decreased P-gp's drug efflux activity. It is important to note that while C2 re-sensitized the HCT116/L-OHP cells to L-OHP for apoptosis, it also triggered a protective autophagic pathway. The expression levels of cleaved caspase-3 and Beclin 1 steadily rose. Expression of PI3K, phosphorylated AKT, and mTOR were decreased, while p53 increased. We demonstrated that the anthraquinone derivative C2 acts as an L-OHP sensitizer and reverses resistance to L-OHP in HCT116/L-OHP cells. It suggests that C2 can induce autophagy in HCT116/L-OHP cells by mediating p53 and the PI3K/AKT/mTOR signaling pathway.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper mainly discusses how anthraquinone compound C2 enhances oxaliplatin-induced colorectal cancer cell death and triggers autophagy through the PI3K/AKT/mTOR signaling pathway. In the study, the authors found that C2 could reverse the resistance of HCT116/L-OHP colorectal cancer cells to oxaliplatin, and inhibit tumor growth in in vivo and in vitro experiments. C2 reduced the expression levels of P-gp and BCRP genes, decreased drug efflux, restored sensitivity of cells to oxaliplatin, and induced a protective autophagy process. Additionally, C2 promoted autophagy by regulating the p53 and PI3K/AKT/mTOR signaling pathways, potentially enhancing the chemotherapeutic effect of oxaliplatin. The purpose of the paper is to reveal the mechanism of C2 enhancing the anti-tumor activity of oxaliplatin and provide new strategies for overcoming chemotherapy resistance in colorectal cancer.